Did you know?

On February 13, 2024, Vistagen Therapeutics Inc ( NASDAQ:VTGN) released its 8-K filing, detailing the financial results for its fiscal year 2024 third quarter ended December 31, 2023, and provided ...VistaGen Therapeutics. Phone: (650) 577-3606. Email: [email protected]. Company Profile VistaGen Therapeutics, Inc. Industry: Pharmaceuticals & Biotechnology Website: https://vistagen.com. PALISADE ...19 Feb 2021 ... Shawn Singh has served as VistaGen's Chief Executive Officer since August 2009; he joined the Board of Directors in 2000. Mr. Singh has nearly ...Iovance Biotherapeutics Inc. -18.48%. $3.76B. VTGN | Complete Vistagen Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock …Get the latest Vistagen Therapeutics Inc (VTGN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …Young Living Essential Oils is a company that specializes in providing natural, therapeutic-grade essential oils and oil-infused products. Their website is a great resource for tho...About VistaGen VistaGen Therapeutics is a multi-asset, clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and certain CNS diseases and disorders where current treatments are inadequate, resulting in high unmet need.On April 25, 2024, Vistagen Therapeutics, Inc. (the "Company") issued a press release to announce positive results from a previously unreported randomized, double-blind, placebo-controlled, crossover Phase 2A pilot study of PH15, the Company's investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue.Vistagen’s fasedienol is an innovative, rapid-onset investigational pherine nasal spray in Phase 3 clinical development in the U.S. for the acute treatment of anxiety in adults with social anxiety disorder (SAD). Designed for intranasal administration in low microgram doses, the proposed mechanism of action (MOA) of fasedienol is novel and ...Young Living Essential Oils is a company that specializes in providing natural, therapeutic-grade essential oils and oil-infused products. Their website is a great resource for tho...VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system.VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing new generation medicines for depression, SAD and other CNS diseases and disorders with high unmet need.SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders ...VistaGen terapéutica, Inc. Volver a Subvenciones. Premios totales: 1. Valor del premio: $971,558. Tipo de institucion: Con fines de lucro. Nombre corto:.Vistagen’s sixth investigational candidate is an oral prodrug with potential to modulate NMDA receptor activity. At Vistagen, we are passionate about delivering differentiated treatments that set new standards of care for people living with anxiety, depression, and other neurological disorders.VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities. ... Vistagen is developing an innovative pipeline of neuroscience medications with ...Vistagen Therapeutics, Inc. VTGN on Nasdaq · This company's Exchange Act registration has been revoked · This company's Exchange Act registration as a Municip...Vistagen Pipeline (Vistagen) The company’s lead program, Fasedienol (PH94B), is a neuroactive nasal spray that could potentially be a breakthrough in the management of social anxiety disorder (SAD).VistaGen Therapeutics stock is diving lower on poor results from a clinical trial. This saw a Phase 3 study of PH94B fail to meet its primary endpoint. This has heavy trading dragging the company ...(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of VistaGen Therapeutics, Inc. (the "Company"), Forms 3, 4 and 5 (including amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, and the rules and regulations thereunder;Vistagen Fiscal Year 2024 Third Quarter Corporate Update Conference Call. Feb 13, 2024 at 2:00 PM PST. Webcast.Discover real-time Vistagen Therapeutics, Inc. Common Stock (VTGN) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety ...Vistagen is advancing therapeutics with the potential to be faster-aPsychedelic therapy, also known as psychedelic-assisted psychotherapy Earnings Estimate Revisions for VistaGen Therapeutics, Inc. This company is expected to earn -$0.28 per share for the fiscal year ending March 2023, which represents a year-over-year change of -12%.VistaGen Therapeutics is a clinical-stage biopharmaceutical company developing new generation medicines for multiple CNS diseases and disorders with high unmet need. VistaGen's CNS pipeline includes three drug candidates (AV-101, PH10, and PH94B) with potential for at-home use, rapid-onset therapeutic benefits and exceptional … Vistagen’s sixth investigational candidate is an oral SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 2, 2023-- Vistagen Therapeutics, Inc. (“Vistagen”) (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (“CNS”) disorders, today announced the pricing of a $100 million underwritten offering of its ... Apr 22, 2024 ... VistaGen Therapeutics Inc's AV-10

A beaten down micro-cap biotech company, Vistagen Therapeutics Inc., notched its best day ever, surging by as many as four digits after its experimental nasal …Vistagen is currently preparing for Phase 2A development of AV-101, on its own or with collaborators, as a treatment for one or more neurological disorders involving the NMDAR. Multiple studies have shown AV-101 to be safe and well-tolerated, and a range of preclinical studies indicate potential in multiple indications, including levodopa ...Vistagen Therapeutics, Inc. VTGN on Nasdaq · This company's Exchange Act registration has been revoked · This company's Exchange Act registration as a Municip...Shawn Singh has served as our Chief Executive Officer since August 2009; he joined our Board of Directors in 2000. Mr. Singh has nearly 30 years of experience working with private and public biotechnology, medical device, and pharmaceutical companies, a venture capital firm, and a profitable contract research and development organization (CRO ...

fink. 10/14/23 1:04 PM. Post #4,990. Re: #4,989: @The_Q - A buddy told me this stock is $50-70. They have an impressive pipeline. But it's a pharma play. A time suck. They are in phase 3 for their first drug. Once they get those results they … Shawn Singh has served as our Chief Executive Officer since August 2009; he joined our Board of Directors in 2000. Mr. Singh has nearly 30 years of experience working with private and public biotechnology, medical device, and pharmaceutical companies, a venture capital firm, and a profitable contract research and development organization (CRO ... EX-101.INS - XBRL INSTANCE DOCUMENT: Jun 30, 2020: 10-K: Annual report which provides a comprehensive overview of the company for the past year…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- VistaGen Therap. Possible cause: The average VistaGen Therapeutics salary ranges from approximately $74342 per year for Of.